ScripTo say that 2022 has gotten off to a rough start for investors that back biopharmaceutical companies would be an understatement. The Nasdaq Biotechnology Index (NBI) is down 14.3% year-to-date and the
In VivoCompany Changes BISHOP , Kathie M., PhD To: Otonomy Inc. , CSO (November) From: Tioga Pharmaceuticals, CSO Phone: 858-242-5200 BOGATYRENKO , Yulii To: TherapeuticsMD Inc. , SVP, Bus. Dev.
In VivoCompany Changes ADAMS , Brad To: ACell Inc. , VP, Sales (August) From: Smith & Nephew Inc., EVP, Commercial Phone: 410-715-1700 BALLANTYNE , C. Evan To: Accera Inc. , CFO (August) From: A